Evaluation of Response Rate to Pre-Operative Docetaxel + Herceptin Study Part A and Docetaxel Study Part B in Locally Advanced Breast Cancer Patients, Stratified by HER2-Status Trial - PHASE II [(Herceptin Docetaxel Neoadjuvant) HEDON].
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Anastrozole; Cyclophosphamide; Docetaxel; Epirubicin; Goserelin; Tamoxifen; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms PHASE II HEDON
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database).
- 12 Jul 2011 Planned End Date added to 30 Dec 2010 as reported by European Clinical Trials Database
- 12 Jul 2011 Status changed from active, no longer recruiting to recruiting as reported by European Clinical Trials Database.